Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

venetoclax 157Cytarabine 117Cyclophosphamide 110Specimen Handling 103Azacitidine 103fludarabine 89Biopsy 78Rituximab 50Methotrexate 45Daunorubicin 45fludarabine phosphate 41Vincristine 38Dexamethasone 37Injections 36Magnetic Resonance Spectroscopy 35Decitabine 35Granulocyte Colony-Stimulating Factor 32blinatumomab 31Mycophenolic Acid 30Idarubicin 30Whole-Body Irradiation 29ibrutinib 27Tacrolimus 27Prednisone 27Etoposide 27Doxorubicin 27Busulfan 27acalabrutinib 24Melphalan 24Filgrastim 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
incomplete Freund's adjuvant × Other hematologic neoplasm × 90 days × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡